Teva (TEVA) Q2 FY26 earnings call

Teva delivered a solid Q2 FY26, with its innovative portfolio (AUSTEDO, UZEDY, AJOVY) driving significant revenue growth and expanding gross margins, despite headwinds from generic REVLIMID erosion. The company raised its full-year revenue guidance and is progressing towards its 2027 operating margin and debt targets, reflected in a recent investment-grade rating upgrade. Strategic capital allocation and a robust pipeline with multiple near-term launches underpin confidence in future growth.